# A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

> **NCT04419623** · PHASE1 · COMPLETED · sponsor: **Telios Pharma, Inc.** · enrollment: 7 (actual)

## Conditions studied

- COVID-19
- Sars-CoV2
- Cancer
- Solid Tumor
- Carcinoma
- Blood Cancer

## Interventions

- **DRUG:** TL-895

## Key facts

- **NCT ID:** NCT04419623
- **Lead sponsor:** Telios Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-09
- **Primary completion:** 2020-09-22
- **Final completion:** 2020-12-15
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2021-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04419623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04419623, "A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04419623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*